Compare SACH & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SACH | SCLX |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4M | 34.4M |
| IPO Year | 2016 | 2020 |
| Metric | SACH | SCLX |
|---|---|---|
| Price | $0.91 | $4.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 165.1K | 25.6K |
| Earning Date | 11-04-2026 | 11-13-2026 |
| Dividend Yield | ★ 21.74% | N/A |
| EPS Growth | ★ 104.30 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $57,500,000.00 | $30,253,000.00 |
| Revenue This Year | $94.91 | $118.16 |
| Revenue Next Year | N/A | $186.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $4.20 |
| 52 Week High | $1.45 | $27.00 |
| Indicator | SACH | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 31.54 |
| Support Level | $0.91 | $4.20 |
| Resistance Level | $0.99 | $5.60 |
| Average True Range (ATR) | 0.03 | 0.32 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 19.82 | 10.66 |
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.